Net Profit Margin
since 2005
Paying user area
Try for free
Illumina Inc. pages available for free this week:
- Cash Flow Statement
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Present Value of Free Cash Flow to Equity (FCFE)
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Illumina Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Illumina Inc., net profit margin, long-term trends, calculation
| Net profit margin | = | 100 | × | Net income (loss) attributable to Illumina stockholders1 | ÷ | Revenue1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2020 | = | 100 | × | ÷ | |||
| Dec 29, 2019 | = | 100 | × | ÷ | |||
| Dec 30, 2018 | = | 100 | × | ÷ | |||
| Dec 31, 2017 | = | 100 | × | ÷ | |||
| Jan 1, 2017 | = | 100 | × | ÷ | |||
| Jan 3, 2016 | = | 100 | × | ÷ | |||
| Dec 28, 2014 | = | 100 | × | ÷ | |||
| Dec 29, 2013 | = | 100 | × | ÷ | |||
| Dec 30, 2012 | = | 100 | × | ÷ | |||
| Jan 1, 2012 | = | 100 | × | ÷ | |||
| Jan 2, 2011 | = | 100 | × | ÷ | |||
| Jan 3, 2010 | = | 100 | × | ÷ | |||
| Dec 28, 2008 | = | 100 | × | ÷ | |||
| Dec 30, 2007 | = | 100 | × | ÷ | |||
| Dec 31, 2006 | = | 100 | × | ÷ | |||
| Jan 1, 2006 | = | 100 | × | ÷ |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
1 US$ in millions
The financial data reveals significant fluctuations and overall growth trends over the examined periods. The net income attributable to stockholders demonstrates considerable volatility, with notable negative earnings early on, followed by a general recovery and growth trajectory.
- Net Income (Loss) Attributable to Stockholders
- Initially, the company experienced substantial losses, with a minimal negative figure in early 2006 and an exacerbated loss by the end of 2007. From 2008 onwards, net income mostly remained positive, showing a strong upward trend notably between 2014 and 2019, peaking in 2019. The figure then declined in 2020 but remained significantly above early-period levels.
- Revenue
- Revenue showed a consistent upward trend throughout the entire timeline. Beginning at a relatively low value in 2006, revenue expanded steadily year-over-year, reaching its highest point in 2019 before a slight decrease in 2020. This growth reflects ongoing expansion and possibly increased market presence or sales volume.
- Net Profit Margin
- The net profit margin displayed considerable variation, particularly during the initial years with negative and low percentages, reflecting early losses and lower profitability. From 2010, the margin improved and stabilized into a positive range, peaking around 2017 and 2018. Although there was some decline in margin in 2020, overall profitability has strengthened compared to the early years.
In summary, the data indicates the company has moved from an initial phase of financial instability and losses to a period of consistent growth in revenue and profitability. Despite some volatility in net income and profit margins, the overall trend is positive, highlighting enhanced financial performance and operational efficiency over time.
Comparison to Competitors
Illumina Inc., net profit margin, long-term trends, comparison to competitors
| Illumina Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2020 | |||||||||||||
| Dec 29, 2019 | |||||||||||||
| Dec 30, 2018 | |||||||||||||
| Dec 31, 2017 | |||||||||||||
| Jan 1, 2017 | |||||||||||||
| Jan 3, 2016 | |||||||||||||
| Dec 28, 2014 | |||||||||||||
| Dec 29, 2013 | |||||||||||||
| Dec 30, 2012 | |||||||||||||
| Jan 1, 2012 | |||||||||||||
| Jan 2, 2011 | |||||||||||||
| Jan 3, 2010 | |||||||||||||
| Dec 28, 2008 | |||||||||||||
| Dec 30, 2007 | |||||||||||||
| Dec 31, 2006 | |||||||||||||
| Jan 1, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Illumina Inc., net profit margin, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Illumina Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2020 | ||
| Dec 29, 2019 | ||
| Dec 30, 2018 | ||
| Dec 31, 2017 | ||
| Jan 1, 2017 | ||
| Jan 3, 2016 | ||
| Dec 28, 2014 | ||
| Dec 29, 2013 | ||
| Dec 30, 2012 | ||
| Jan 1, 2012 | ||
| Jan 2, 2011 | ||
| Jan 3, 2010 | ||
| Dec 28, 2008 | ||
| Dec 30, 2007 | ||
| Dec 31, 2006 | ||
| Jan 1, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
Comparison to Industry (Health Care)
Illumina Inc., net profit margin, long-term trends, comparison to industry (health care)
| Illumina Inc. | Health Care | |
|---|---|---|
| Dec 31, 2020 | ||
| Dec 29, 2019 | ||
| Dec 30, 2018 | ||
| Dec 31, 2017 | ||
| Jan 1, 2017 | ||
| Jan 3, 2016 | ||
| Dec 28, 2014 | ||
| Dec 29, 2013 | ||
| Dec 30, 2012 | ||
| Jan 1, 2012 | ||
| Jan 2, 2011 | ||
| Jan 3, 2010 | ||
| Dec 28, 2008 | ||
| Dec 30, 2007 | ||
| Dec 31, 2006 | ||
| Jan 1, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).